09 Nov 2010 12:03

DR LAURE PLASMATECHN

07114204829

S. 1

Doc Code: Oath

Document Description: Oath or declaration filed

PTO/SB/01 (04-09)

PTO/SB01 (04-01)

Approved for use through distinction (0.480 cm-4-00)

U.S. Patenti and Trademark Office U.S. DEPARTMENT OF COMMERCE

U.S. Patenti and Trademark Office U.S. DEPARTMENT OF COMMERCE

THE PATENTIAL A TO A STREET OF THE PATENTIAL O

## Attorney Docket **DECLARATION FOR UTILITY OR** 14430 Number DESIGN First Named Inventor Dr. Stefan LAURE PATENT APPLICATION COMPLETE IF KNOWN (37 CFR 1,63) Application Number 10/586009 Declaration Submitted After Initial Fling (suntherpe Filing Date With Inline (37.CFR 1.16(j)) Art Unit required) Exeminer Name

I hereby declare that: (1) Each inventor's residence, making address, and citizenship are an stated below next to their name; and (2) I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention (titled: PLASMA TREATMENT OF LARGE-SCALE COMPONENTS (Title of the Invention) the application of which is attached hereto OR Was filed on (MMA/DDAYYYY) 07/11/2006 se United States Application Number or PCT International Application Number 10/586009 \_BAC Was amended on (MM/DD/YYYYY) (if appticable). I besoly state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above. I ecknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation in part application. Authorization To Permit Access To Application by Participating Offices If checked, the undereigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (EPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (KIPO), and Japan Patent Cares (ar-C), the Acresia immediate Property Cinco (Astrony, one vivers emercials interesting from the interesting property cincos in which is foreign application claiming priority to the above-identified patent application is field access to the above-identified patent application. See 27 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, IPO, KIPO, WIPO, or other interestual property office in which a foreign application claiming primity to the above-identified patent application is fied to have access to the above-identified petent application. in accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the above identified patent application with respect In secondance will 37 CFR 1.14(1)(3), screens will be provided to a copy of the short-inequality participation to which the shore-identified patent application—as filled, 2) any foreign application to which the shore-identified patent application claims priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filled in the above-identified patent application; and 3) any U.S. application-as-filled from which benefit is sought in the above-identified patent application. in accordance with 37 CFR 1.14(e), access may be provided to information concerning the date of filing the Authorization to Parmit Access to Application by Participating Offices.

This bodiesion of information is required by 25 U.S.C. 115 and 37 CFR 1.03. The information is sequenced to obtain or return a beneal by the public selects by the USPTO in process) on application. Commission in greatest by 80 U.S.C. 122 and 37 CFR 1.11 and 1.94. This conscious is estimated in time 21 related by 80 U.S.C. 122 and 37 CFR 1.11 and 1.94. This conscious is estimated in time 21 related to complete, leaduring gathering, properties, and submitting the completed application from to the USPTO. Time will very depending upon the local-stand conservations as the conservation of the conservation of the USPTO. The will very depending upon the local-stand conservation of the C

If you need assistance in completing the term, cut \$-200-PTQ-9109 and select option 2.

09 Nov 2010 12:03 DR LAURE PLASMATECHN

07114204829

**8.** 2

PTO/SBAP (04-09)
Appeared for use through optionzers. Office (04-09)
U.S. Peters and Tradordate Office; U.S. DEPARTMENT OF COMMISSION
U.S. DEPARTMENT OF COM DECLARATION — Utility or Design Patent Application Chilm of Poreign Priority Sensitis I hereby claim foreign priority benefits under 35 U.S.C. 149(a)-(d) or (f), or 365(b) of any foreign application(s) for passnt, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at teast one country other than the United Stress of America, listed below such have also identified below, by checking the box, any foreign application for pasent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed. Prior Foreign Application Foreign Flang Date Priority Certified Copy Attached? Country Number(s) (MSM/DD/YYYYY) Not Claimed 102004002878.8 DΕ 01/15/2004

[Page 2 of 3)

Additional foreign application number(s) are listed on a supplemental priority data sheet PTO/SB/02B attached hareto.

09 Nov 2010 12:03

DR LAURE PLASMATECHN

07114204829

8.3

PROFSBOT (04-09) Approved for use through 687302019. CRIS 0851-0022 LLS. Palent and Trademark Otion; U.S. SEPARTHERT OF COUNTRICE. C & collection of information unless it contains a wall Otids control number. Under the Paperwork Restriction Act of 1985, no persons are required to respond to a collection of informely DECLARATION — Utility or Design Patent Application The address Direct all Correspondence associated with 61142 OR cortespondence to: address below Customer Number: Name Address Cay Вы Country Emat WARNING: Petitionariapplicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity that. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the Comer than a creek or ement card autranazation route in a case a business in payment purposes, you want to the USPTO to support a petition or an application. If this type of personal adamation is included in documents submitted to the USPTO, petitioners/applicants should consider redaming such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a petent application is available to the public after publication of to up CGT LC. Prosecretary or services that one record or a param approximate avanages to the publication request in configurate with 37 CFR 1.213(e) is made in the application) or issuance of a patient. Purificance, the record from an abandonad application may also be available to the public if the application is referenced in a published application or an issued patient (see 37 CFR 1.14). Charica and credit card authorization forms PTC-2036 submitted for payment purposes are not retained in the application file and therefore are not publicly available. Pro-ZLIS stormmen or payment purposes are not retering in the approximation and are successful purposes are not present extensions. Petitions deposition (such as the PTO/SB/O1) are placed into the Privacy Act system of records DEPARTMENT OF COMMERCE, COMMERCE-PAT-7, System name: Patent Application Files. Decuments not reterined in an application file (such as the PTO-2038) are placed into the Privacy Act system of COMMISTERCE/PAT-TM-10, System name: Deposit Accounts and Electronic Funds Transfer Profiles. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful tales statements and the like so made are purishable by time or imprisonment, or both, under 18 U.S.C. 1001 and that such within tales statements may jeopardize the validity of the application or any peters issued thereon. NAME OF SOLE OR FIRST DOVENTOR: A petition has been filed for this unaigned inventor Given Name (first and middle jif any) Family Name or Surname Dr. Stefan **AURE** Inventor's Signature 09 November 2010 Country Chizanship Stuttgart DE DE Maining Address Schwanenstrasse 12 City Zio Country Stuttgart 70329 DE orti po boman grisid des evitatnoquiqui lagis ¢ 16 andrawii la explainment alumits) PTO/SR/02A or UZLR infiniting horses

5.4

09 Nov 2010 12:03

DR LAURE PLASMATECHN

07114204829

## **Privacy Act Statement**

The Privacy Act of 1974 (P.L. 93-879) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 36 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Preedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.

  2. A record from this system of records may be disclosed, as a routine use, in the course of
- presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an Individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an international Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

  6. A record in this system of records may be disclosed, as a routine use, to enother federal
- agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or higher designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce)
- directive. Such disclosure shall not be used to make determinations about individuals. 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the appocation pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 161. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which bacame abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.